Results 61 to 70 of about 2,631,955 (205)

Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma

EJC Skin Cancer
Objective: To evaluate the relation between solar elastosis and tumor mutation burden (TMB) in a large clinically annotated cohort of stage II and III melanoma patients.
Cecilia Lezcano, Li Luo, Ronglai Shen, Irene Orlow, Nancy E. Thomas, Marianne Berwick, Klaus J. Busam   +6 more
doaj   +1 more source

Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics

Cancer Medicine, 2023
Esophageal cancer (EC) is an aggressive malignancy that accounts for numerous cancer‐related deaths worldwide. The multimodal combination therapy approach can be potentially used to treat EC effectively.
Chenchun Fu, Shicheng Feng, Sheng Wang, Xiangyu Su   +3 more
doaj   +1 more source

Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer

Frontiers in Medicine, 2021
Purpose: To comprehensively analyze N6-methyladenosine modification patterns in bladder tumors and to further systematically explore the inherent relationships between these modification patterns and multiomic tumor characteristics.Materials and Methods:
Jingchao Liu, Jingchao Liu, Jianlong Wang, Meng Wu, Wei Zhang, Wei Zhang, Lingfeng Meng, Lingfeng Meng, Jiawen Wang, Jiawen Wang, Zhengtong Lv, Zhengtong Lv, Haoran Xia, Haoran Xia, Yaoguang Zhang, Yaoguang Zhang, Jianye Wang, Jianye Wang   +17 more
doaj   +1 more source

Tumor Mutation Burden and Cancer Treatment [PDF]

JAMA Oncology, 2021
Michael J, Fusco, Howard Jack, West, Christine M, Walko   +2 more
openaire   +2 more sources

Supplementary Table 8 from Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade

, 2019
Comparison of Tumor Mutation Burden and Microsatellite Status for Patients Evaluated for Response to Immune Checkpoint ...
Steve Lu (6678503), James R. White (9416009), Luis A. Diaz (79765), Dung T. Le (14984627), David Riley (3044703), Jennifer N. Durham (15013647), Robert A. Anders (10076582), Andrew Georgiadis (15006537), Sam Angiuoli (81116), Erika Gedvilaite (15013668), Laurel A. Keefer (15013650), Ellen L. Verner (15013662), Bjarne R. Bartlett (15013653), Derek Murphy (15013659), Mark Sausen (15006549), Magdalena Zielonka (15013656), Siân Jones (6986), Victor E. Velculescu (14937201), Finey Ruan (15013665)   +18 more
core   +1 more source

Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial

Frontiers in Oncology, 2022
IntroductionThe poor prognosis of ovarian carcinoma (OvC) is due to the advanced stage at diagnosis, a high risk of relapse after first-line therapies, and the lack of efficient treatments in the recurrence setting. Circulating tumor DNA (ctDNA) analysis
Renaud Sabatier, Renaud Sabatier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, Jihane Pakradouni, José Adelaide, Magali Provansal, Maria Cappiello, Frédérique Rousseau, Max Chaffanet, Daniel Birnbaum, Emilie Mamessier, Anthony Gonçalves, Anthony Gonçalves, François Bertucci, François Bertucci   +16 more
doaj   +1 more source

Additional file 2: of Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

, 2019
Impact of baseline patients’ and disease characteristics on tumor mutation burden, ctDNA and cfDNA.
Dennis DĂścker (4831773), Florian Battke (139089), Peter Martus (158797), Martin Schulze (365913), Saskia Biskup (40279), Maximilian Frick (6417680), Teresa Amaral (4558276), Nicola Tietze (6949829), Claus Garbe (48881), Bernhard Klumpp (6949826), Thomas Eigentler (103619), Tobias Sinnberg (209299), Chung-Ting Han (6949820), Maria Kopp (6949823), Ulrike Keim (355963), Andrea Forschner (408187), Dirk Hadaschik (216162), Stephanie Weißgraeber (6949832)   +17 more
core   +1 more source

Quantified pathway mutations associate epithelial-mesenchymal transition and immune escape with poor prognosis and immunotherapy resistance of head and neck squamous cell carcinoma

BMC Medical Genomics
Background Pathway mutations have been calculated to predict the poor prognosis and immunotherapy resistance in head and neck squamous cell carcinoma (HNSCC).
Yuhong Huang, Han Liu, Bo Liu, Xiaoyan Chen, Danya Li, Junyuan Xue, Nan Li, Lei Zhu, Liu Yang, Jing Xiao, Chao Liu   +10 more
doaj   +1 more source

BRAF status as a predictive factor for response in isolated limb perfusion

International Journal of Hyperthermia, 2019
Background: Isolated limb perfusion (ILP) is a treatment option for unresectable in-transit melanoma metastases of the extremities. Approximately two-thirds of the patients have a complete response, and known predictive factors mainly regard tumor burden.
Valerio Belgrano, Jan Mattsson, Jonas Nilsson, Roger Olofsson Bagge, Dimitrios Katsarelias   +4 more
doaj   +1 more source

LINC02126 is a potential diagnostic, prognostic and immunotherapeutic target for lung adenocarcinoma

BMC Pulmonary Medicine, 2022
Background Adenocarcinoma has long been an independent histological class of lung cancer, which leads to high morbidity and mortality. We aimed to investigate the contribution of LINC02126 in lung adenocarcinoma.
Junbin Wang, Jixian Liu, Qinghua Hou, Mengmeng Xu   +3 more
doaj   +1 more source